Home / Market News / $NAMS

$NAMS news and market catalysts

The 6 most recent market catalysts affecting $NAMS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 2 high impact 0 bullish 3 bearish Biotechnology
Nov 4, 2026 Corporate Catalyst Bearish Impact 65
NewAmsterdam Pharma Reports Third Quarter 2026 Financial Results
NewAmsterdam Pharma released its Q3 2026 financial results, reporting a net loss of $0.14 per share. As a clinical-stage biopharmaceutical company, a net loss is expected as it inv…
Oct 5, 2026 Corporate Catalyst Bearish Impact 55
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42
RBC Capital's decision to maintain an 'Outperform' rating suggests continued confidence in NewAmsterdam Pharma Co's underlying business and future potential. However, the reduction…
Sep 29, 2026 Corporate Catalyst Neutral Impact 65
NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease
NewAmsterdam Pharma has dosed the first participant in its SPINOZA Phase 2b clinical trial, investigating obicetrapib for preclinical Alzheimer's disease. This is a significant dev…
Sep 21, 2026 Corporate Catalyst Neutral Impact 85
NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia
NewAmsterdam Pharma has received marketing authorization from the European Commission for Ubeslo and Evlarco, two non-statin medicines for primary hypercholesterolaemia. This is a …
Sep 8, 2026 Market Technicals Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target
HC Wainwright & Co. analyst Lander Egaña Gorroño has reaffirmed a 'Buy' rating and a $52 price target for NewAmsterdam Pharma Co (NAMS). This action signals that the analyst's inve…
Aug 5, 2026 Corporate Catalyst Bearish Impact 92
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
NewAmsterdam Pharma's Q2 earnings report reveals a mixed financial performance. The company's earnings per share (EPS) of $(0.52) significantly missed analyst estimates and showed …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.